H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析

◆英語タイトル:H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1329
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

H. Lundbeck AS (LUN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of diseases such as Alzheimer’s disease, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington’s disease, among others. It operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS Key Recent Developments

Mar 30,2020: Failed studies prompt Lundbeck to terminate foliglurax in Parkinson’s disease, Lu AG06466 in Tourette syndrome
Mar 11,2020: Aarhus University and the pharmaceutical industry join forces on open innovation – a pathway to new medicines
Mar 04,2020: Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
Feb 24,2020: Lundbeck’s Vyepti secures US approval for migraine prevention
Jan 15,2020: NNIT and Lundbeck extend collaboration

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
H. Lundbeck AS – Key Facts
H. Lundbeck AS – Key Employees
H. Lundbeck AS – Key Employee Biographies
H. Lundbeck AS – Major Products and Services
H. Lundbeck AS – History
H. Lundbeck AS – Company Statement
H. Lundbeck AS – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
H. Lundbeck AS – Business Description
Product Category: Abilify Maintena
Overview
Performance
Product Category: Brintellix/Trintellix
Overview
Performance
Product Category: Cipralex/Lexapro
Overview
Performance
Product Category: Effects from Hedging
Performance
Product Category: Northera
Overview
Performance
Product Category: Onfi
Overview
Performance
Product Category: Other pharmaceuticals
Performance
Product Category: Other Revenue
Performance
Product Category: Rexulti
Overview
Performance
Product Category: Sabril
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Target Markets
Performance
Geographical Segment: North America
Performance
R&D Overview
H. Lundbeck AS – Corporate Strategy
H. Lundbeck AS – SWOT Analysis
SWOT Analysis – Overview
H. Lundbeck AS – Strengths
H. Lundbeck AS – Weaknesses
H. Lundbeck AS – Opportunities
H. Lundbeck AS – Threats
H. Lundbeck AS – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
H. Lundbeck AS, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 04, 2020: Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
Jan 15, 2020: NNIT and Lundbeck extend collaboration
Nov 05, 2019: H. Lundbeck: Double-digit growth for all strategic brands in 9M 2019 and FY 2019 guidance raised
Nov 05, 2019: Double-digit growth for all strategic brands in 9M 2019 and FY 2019 guidance raised
Sep 17, 2019: Lundbeck signs $1.95bn deal to buy Alder BioPharmaceuticals
Aug 14, 2019: Double-Lundbeck’s digit growth for all strategic brands and DKK 8.5 billion in revenue and DKK 2.3 billion in EBIT
Aug 14, 2019: Lundbeck appoints new EVP, People & Communication
May 30, 2019: Hyphens Pharma signs exclusive distribution agreement with Lundbeck for Vietnam
May 08, 2019: H. Lundbeck: Double-digit growth for all strategic brands and DKK 4,234 million in revenue and DKK 1,200 million in EBIT
May 07, 2019: Lundbeck to purchase Abide Therapeutics in $400m deal
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
H. Lundbeck AS, Key Facts
H. Lundbeck AS, Key Employees
H. Lundbeck AS, Key Employee Biographies
H. Lundbeck AS, Major Products and Services
H. Lundbeck AS, History
H. Lundbeck AS, Subsidiaries
H. Lundbeck AS, Key Competitors
H. Lundbeck AS, Ratios based on current share price
H. Lundbeck AS, Annual Ratios
H. Lundbeck AS, Annual Ratios (Cont...1)
H. Lundbeck AS, Annual Ratios (Cont...2)
H. Lundbeck AS, Interim Ratios
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
H. Lundbeck AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
H. Lundbeck AS, Performance Chart (2015 - 2019)
H. Lundbeck AS, Ratio Charts
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bata India Limited:企業の戦略・SWOT・財務分析
    Bata India Limited - Strategy, SWOT and Corporate Finance Report Summary Bata India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mauna Kea Technologies SAS (MKEA)-医療機器分野:企業M&A・提携分析
    Summary Mauna Kea Technologies SAS (MKT) is a medical device company that develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. The company’s product includes cellvizio. Its cellvizio is an endomicroscopy platform that provides micr …
  • Neovasc Inc (NVCN):医療機器:M&Aディール及び事業提携情報
    Summary Neovasc Inc (Neovasc) is a medical device manufacturing company that manufactures, develops, and sells cardiovascular disease products. The company’s products include Neovasc reducer, Neovasc tiara, and Neovasc tissue products. Its Neovasc tiara is a novel transcatheter device that is design …
  • Tallgrass Energy Partners, LP (TEP):石油・ガス:M&Aディール及び事業提携情報
    Summary Tallgrass Energy Partners LP (Tallgrass Energy), a midstream oil and gas company.. It offers natural gas transportation and storage services to customers in the Rocky Mountains and Midwest regions of the US. The company also provides crude oil transportation to customers in Wyoming, Colorado …
  • The Scotts Miracle-Gro Company (SMG):企業の財務・戦略的SWOT分析
    The Scotts Miracle-Gro Company (SMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Innate Pharma SA (IPH)-製薬・医療分野:企業M&A・提携分析
    Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclo …
  • resTORbio Inc (TORC):製薬・医療:M&Aディール及び事業提携情報
    Summary resTORbio Inc (resTORbio) a subsidiary of Puretech Health plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of aging-related diseases. Its pipeline product candidate RTB101, an orally administered, small mo …
  • UnionBank of the Philippines (UBP):企業の財務・戦略的SWOT分析
    UnionBank of the Philippines (UBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • SSP Group Limited (Foodservice):企業の戦略・SWOT・財務情報
    SSP Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary SSP Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Adecco Group AG :企業の戦略・SWOT・財務情報
    Adecco Group AG - Strategy, SWOT and Corporate Finance Report Summary Adecco Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • KPMG International Coop:企業の戦略的SWOT分析
    KPMG International Coop - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Halt Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Halt Medical Inc (Halt Medical) is a healthcare service center that develops, manufactures and commercializes medical treatment for women with symptomatic uterine fibroids. The center offers Acessa System, a minimally invasive laparoscopic outpatient procedure to treat uterine fibroids. It o …
  • Spicejet Limited
    Spicejet Limited - Strategy, SWOT and Corporate Finance Report Summary Spicejet Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Severoceske doly as:企業の戦略・SWOT・財務情報
    Severoceske doly as - Strategy, SWOT and Corporate Finance Report Summary Severoceske doly as - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Protagonist Therapeutics Inc (PTGX):企業の財務・戦略的SWOT分析
    Protagonist Therapeutics Inc (PTGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Vexim SA – Product Pipeline Analysis, 2018 Uate
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …
  • Cardia Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cardia Inc (Cardia) is a medical device company that designs, manufactures and markets transcatheter septal occluders for cardiac defect patients. The company offers products such as ultrasept ASD occluder, ultrasept LAA occluder, ultrasept PFO occluder, fontan occluder, ultrasept cribriform …
  • National Jewish Health:製薬・医療:M&Aディール及び事業提携情報
    Summary National Jewish Health (NJH), formerly National Jewish Medical and Research Center is a healthcare service provider that offers treatment for pulmonary, cardiac, immune and related disorders. The center conducts programs in the therapeutic areas of allergy, asthma, bronchicardiology, bronchi …
  • Marathon Petroleum Corporation (MPC)-石油・ガス分野:企業M&A・提携分析
    Summary Marathon Petroleum Corporation (MPC) is a downstream energy company, which refines, markets and transports petroleum products. It owns and operates refineries in the Gulf Coast and Midwest regions of the US. MPC owns common carrier pipeline systems that transport crude oil and refined produc …
  • Sime Darby Berhad:企業の戦略・SWOT・財務分析
    Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report Summary Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆